Letter by Puri et al Regarding Article, “Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the article by Ray et al1 about major adverse cardiovascular events outcomes in patients with low-density lipoprotein cholesterol (LDL-C) <50 mg/dL. It has been a well-known fact that South Asians have an atherogenic dyslipidemia [high triglycerides and low high-density lipoprotein cholesterol (HDL-C)] at baseline,2 are at higher cardiovascular risk, and develop coronary artery disease ≈1 decade earlier than whites. Hence, guidelines by the Lipid Association of India have laid great …